Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of carboplatin + paclitaxel or gemcitabine with or without bevacizumab in platinum-sensitive recurrent ovarian/peritoneal/fallopian tube cancer
KCT0003484Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, carboplatin, paclitaxel, gemcitabine in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Jul 2009; status: active, not recruiting.
02
Drugs
bevacizumabcarboplatinpaclitaxelgemcitabine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on KCT0003484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003484.